Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Calidi Biotherapeutics, Inc. Common Stock (NY:CLDI)

0.8150 -0.0150 (-1.81%)
Streaming Delayed Price Updated: 12:40 PM EST, Feb 10, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Calidi Biotherapeutics, Inc. Common Stock

< Previous 1 2 3 4 5 Next >
Novel Yeast Cell Platform Promises to Expedite the Development of Immunotherapies
Via Investor Brand Network
Scientists Discover Why Immunotherapy Frequently Fails
Via Investor Brand Network
Circadian Regulation Could Boost Cancer Immunotherapy, New Study Finds
Via Investor Brand Network
Novel Therapy Helps Tumor Cells Welcome Cancer Treatment
Via Investor Brand Network
Scientists Develop Next-Gen Antibodies That Boost the Body’s Cancer Killing Cells
Via Investor Brand Network
Study Discovers Molecule of Gut Bacteria That Boosts Immunotherapy Response
Via Investor Brand Network
Study Suggests mRNA Covid Vaccine Could Boost Cancer Immunotherapy
Via Investor Brand Network
Cornell Researchers Develop Particles That Can Supercharge Immunotherapy
Via Investor Brand Network
New ‘Nanozigzag’ Biomaterial Shows Potential in Revolutionizing Cancer Immunotherapy
Via Investor Brand Network
New Approach Could Increase Response Rates for Cancer Immunotherapy
Via Investor Brand Network
Novel Biomarker Could Predict Resistance to Immunotherapy, Study Finds
Via Investor Brand Network
Study Highlights Increasing Cases of Breast Cancer in Younger Women
Via Investor Brand Network
Study Proposes Overhaul of US Lung Cancer Screening Guidelines
Via Investor Brand Network
News headline image
Calidi Biotherapeutics and Nova Minerals Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
Via ACCESS Newswire
Cancer Immunotherapy Could Be Boosted by Targeting Pathways of DNA Repair
Via Investor Brand Network
What Patients Need to Know About Exercising During Cancer Treatment
Via Investor Brand Network
Study identifies Biomarker to Predict Success of Immunotherapy, Chemo for Breast Cancer
Via Investor Brand Network
Rarest Natural Element Promises to Revolutionize How Cancer is Treated
Via Investor Brand Network
Cancer Immunotherapy Could Be Transformed by Boosting Natural Killer Cells
Via Investor Brand Network
Lung Cancer Screening is Still Woefully Low in the US, Report Shows
Via Investor Brand Network
Topics Death
New LED Therapy Kills Cancer Cells While Sparing Healthy Tissues
Via Investor Brand Network
Researchers Urge Canadians to Donate Toenails, for Science
Via Investor Brand Network
Researchers Discover Why Cancer Immunotherapy Could Be Failing
Via Investor Brand Network
Lund University Researchers Discover Why Leukemia Cells Evade the Immune System
Via Investor Brand Network
Researchers Find That Common Nutrient Could Supercharge the Immune Cells Fighting Cancer
Via Investor Brand Network
How Patients Can Boost Dietary Nutrient Intake During Cancer Treatment
Via Investor Brand Network
Study Finds That Common Sweetener Could Compromise Cancer Treatment Effectiveness
Via Investor Brand Network
TinyGemsBreaks – Calidi Biotherapeutics Inc. (NYSE American: CLDI) to Present at H.C. Wainwright Global Investment Conference
Via Investor Brand Network
New Study Discovers Unexpected Reason for Resistance to Cancer Immunotherapy
Via Investor Brand Network
TinyGemsBreaks – Calidi Biotherapeutics Inc. (NYSE American: CLDI) Closes $6.9 Million Public Offering Including Full Over-Allotment Option
Via Investor Brand Network
< Previous 1 2 3 4 5 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.